Organogenesis Holdings Inc. (ORGO)
Automate Your Wheel Strategy on ORGO
With Tiblio's Option Bot, you can configure your own wheel strategy including ORGO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ORGO
- Rev/Share 3.6665
- Book/Share 3.042
- PB 3.2525
- Debt/Equity 0.16
- CurrentRatio 3.3188
- ROIC -0.019
- MktCap 830004480.0
- FreeCF/Share -0.4071
- PFCF -16.0692
- PE -94.4572
- Debt/Assets 0.08
- DivYield 0
- ROE -0.0257
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 3
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Organogenesis Applauds CMS's Significant Step In Payment Reform
Published: November 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
With evidence-based portfolio including technologies in each FDA category, we believe we are best positioned in the skin substitutes market for 2026 and beyond With evidence-based portfolio including technologies in each FDA category, we believe we are best positioned in the skin substitutes market for 2026 and beyond
Read More
Organogenesis Holdings Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – ORGO
Published: October 17, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)--Organogenesis Holdings Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – ORGO.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
Published: October 13, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Oct. 13, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Organogenesis Holdings Inc. ("Organogenesis" or the "Company") (NASDAQ: ORGO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Organogenesis Holdings Inc. (ORGO) Q4 2024 Earnings Call Transcript
Published: February 27, 2025 by: Seeking Alpha
Sentiment: Neutral
Organogenesis Holdings Inc. (NASDAQ:ORGO ) Q4 2024 Earnings Conference Call February 27, 2025 5:00 PM ET Company Participants Gary S. Gillheeney, Sr. – President and Chief Executive Officer Dave Francisco – Chief Financial Officer Conference Call Participants Brooks O'Neil – Lake Street Capital Markets Ross Osborn – Cantor Fitzgerald Ryan Zimmerman – BTIG Operator Please standby.
Read More
About Organogenesis Holdings Inc. (ORGO)
- IPO Date 2017-01-05
- Website https://organogenesis.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Gary S. Gillheeney
- Employees 869